Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 ^T315I -compound mutations.

Autor: Gleixner KV; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria., Filik Y; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria., Berger D; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria., Schewzik C; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria., Stefanzl G; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria., Sadovnik I; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria., Degenfeld-Schonburg L; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria., Eisenwort G; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria., Schneeweiss-Gleixner M; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria.; Department of Internal Medicine III, Division of Gastroenterology & Hepatology, Medical University of Vienna Austria., Byrgazov K; Children's Cancer Research Institute (CCRI) Vienna, Austria., Sperr WR; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria., Mayer J; Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine, Masaryk University Brno, Czech Republic.; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno Czech Republic., Lion T; Children's Cancer Research Institute (CCRI) Vienna, Austria., Valent P; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna Austria.

Publikováno v: American journal of cancer research [Am J Cancer Res] 2021 Sep 15; Vol. 11 (9), pp. 4470-4484. Date of Electronic Publication: 2021 Sep 15 (Print Publication: 2021).